H.R. 413 · 113th Congress

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

Stage
In committee
Sponsor
Peter Welch
Introduced
2013-01-23
Latest action
2013-02-08 · Referred to the Subcommittee on Health.

Action history

  1. 2013-02-08Referred to the Subcommittee on Health.
  2. 2013-01-25Referred to the Subcommittee on Health.
  3. 2013-01-23Introduced in House
  4. 2013-01-23Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. 2013-01-23Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.